| 21 |
Dong-A ST, SK bioscience, and Onconic Therapeutics are among 7 Innovative Pharmaceutical Companies
|
2025-01-08 |
422 |
| 20 |
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA
|
2025-01-08 |
427 |
| 19 |
CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to STELARA®
|
2024-10-23 |
669 |
| 18 |
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
|
2024-10-23 |
509 |
| 17 |
Dong-A ST's ECG Monitoring Platform Hicardi+ H100 Receives U.S. FDA Approval
|
2024-09-30 |
441 |
| 16 |
Dong-A ST and its subsidiary to codevelop long-acting obesity drug with ImmunoForge
|
2024-08-20 |
516 |
| 15 |
Dong-A ST Presents Preclinical Results of Tau-Targeting Dementia Treatment ‘DA-7503’ at AAIC
|
2024-08-08 |
807 |
| 14 |
DA-1241 Global Phase 2 Part 1 Patient Recruitment Completed
|
2024-04-05 |
696 |
| 13 |
Dong-A ST, STGen Bio, ST Pharm's Triangular Partnership at Songdo Bio Hub
|
2024-04-05 |
1439 |
| 12 |
IMBiologics partners with Dong-A ST for novel antibody drug development
|
2024-02-19 |
710 |
